Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Clin Cancer Res. 2011 Jan 17;17(8):2361–2372. doi: 10.1158/1078-0432.CCR-10-2262

Figure 5. The Smac mimetic restores gemcitabine sensitivity in SMAC-KD cells.

Figure 5

SMAC-KD cells were treated with 50 μM gemcitabine with or without 100 nM control (GT-C) or active (GT-A) Smac mimetic compound for 48 h. (A) Apoptosis was analyzed by flow cytometry. (B) Caspase 3 activation was analyzed by Western blotting. (C) Cytochrome c release was analyzed by Western blotting. (D) Mitochondrial membrane depolarization was analyzed by flow cytometry.